

Cristina Ripoll

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7039210/publications.pdf>

Version: 2024-02-01

67
papers

5,278
citations

147566

31
h-index

114278

63
g-index

75
all docs

75
docs citations

75
times ranked

4377
citing authors

#	ARTICLE	IF	CITATIONS
1	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2276-2286.e6.	2.4	42
2	Baveno VII “Renewing consensus in portal hypertension. <i>Journal of Hepatology</i> , 2022, 76, 959-974.	1.8	890
3	Reply to: “Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma”™. <i>Journal of Hepatology</i> , 2022, 77, 567-568.	1.8	2
4	Open or closed window: That is the question. <i>Journal of Hepatology</i> , 2021, 74, 485-486.	1.8	0
5	Effect of ET“ blockades on portal pressure and hepatic arterial perfusion in patients with cirrhosis: A proof of concept study. <i>Liver International</i> , 2021, 41, 554-561.	1.9	10
6	Isolated bacterial infection without decompensation has no impact on survival of compensated patients with cirrhosis. <i>Liver International</i> , 2021, 41, 1370-1378.	1.9	7
7	First things first! Can bacterial infections be considered as decompensating events per se?. <i>Journal of Hepatology</i> , 2021, 75, 1241-1242.	1.8	1
8	Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter Variant. <i>Hepatology Communications</i> , 2021, 5, 1755-1766.	2.0	3
9	Covert hepatic encephalopathy and spontaneous portosystemic shunts increase the risk of developing overt hepatic encephalopathy. <i>Liver International</i> , 2020, 40, 3093-3102.	1.9	11
10	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1140-1150.	1.8	97
11	Inhibition of Glyoxalase-I Leads to Reduced Proliferation, Migration and Colony Formation, and Enhanced Susceptibility to Sorafenib in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 785.	1.3	12
12	Clinical Utility of a Risk“Adapted Protocol for the Evaluation of Coronary Artery Disease in Liver Transplant Recipients. <i>Liver Transplantation</i> , 2019, 25, 1177-1186.	1.3	16
13	Common NOD2 Risk Variants as Major Susceptibility Factors for Bacterial Infections in Compensated Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00002.	1.3	10
14	It takes two “eyes“to see in depth. <i>Journal of Hepatology</i> , 2019, 70, 790-791.	1.8	1
15	Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. <i>EBioMedicine</i> , 2018, 30, 138-147.	2.7	116
16	The advantage of calling things by the same name. <i>Liver Transplantation</i> , 2018, 24, 581-582.	1.3	0
17	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018, 154, 1694-1705.e4.	0.6	162
18	Covert hepatic encephalopathy leads to distinct alterations in the emotional state, independently of MELD-Score. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, 461-468.	0.2	5

#	ARTICLE	IF	CITATIONS
19	Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis. <i>Liver International</i> , 2018, 38, 102-112.	1.9	21
20	Cardiac function, A key component in evaluation for liver transplant. <i>Liver Transplantation</i> , 2018, 24, 7-8.	1.3	8
21	Comparison of Two Protocols of Carbon Tetrachloride-Induced Cirrhosis in Rats “Improving Yield and Reproducibility. <i>Scientific Reports</i> , 2018, 8, 9163.	1.6	49
22	Left ventricular systolic function is associated with sympathetic nervous activity and markers of inflammation in cirrhosis. <i>Hepatology</i> , 2017, 65, 2019-2030.	3.6	43
23	Pressure volume curves in cirrhosis: More than meets the eye. <i>Journal of Hepatology</i> , 2017, 67, 656-657.	1.8	2
24	Expression of glyoxalase-I is reduced in cirrhotic livers: A possible mechanism in the development of cirrhosis. <i>PLoS ONE</i> , 2017, 12, e0171260.	1.1	17
25	Determinants of platelet count are different in patients with compensated and decompensated cirrhosis. <i>Liver International</i> , 2016, 36, 232-239.	1.9	10
26	The interpretation of hepatic venous pressure gradient tracings “excellent interobserver agreement unrelated to experience. <i>Liver International</i> , 2016, 36, 1160-1166.	1.9	12
27	Noninvasive predictors of fibrosis in NASH with and without cirrhosis, just as good as histology (and Tj ETQq1 1 0.784314 rgBT /Over 3.6 4	3.6	4
28	Effect of Current Therapies Aimed at Preventing Variceal Rebleeding on Other Complications of Cirrhosis. , 2016, , 333-339.		1
29	Secondary Prophylaxis in Special Patient Populations. , 2016, , 317-332.		0
30	Serum Ferritin in Patients With Cirrhosis is Associated With Markers of Liver Insufficiency and Circulatory Dysfunction, but Not of Portal Hypertension. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 784-789.	1.1	11
31	Serum Albumin Can Identify Patients With Compensated Cirrhosis With a Good Prognosis. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 613-619.	1.1	40
32	Hepatic Arterial Vasodilation Is Independent of Portal Hypertension in Early Stages of Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0121229.	1.1	11
33	Characteristic haemodynamic changes of cirrhosis may influence the diagnosis of portopulmonary hypertension. <i>Liver International</i> , 2015, 35, 353-361.	1.9	11
34	Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients. <i>World Journal of Transplantation</i> , 2014, 4, 133.	0.6	18
35	Reply. <i>Hepatology</i> , 2014, 60, 1795-1796.	3.6	0
36	Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. <i>Liver International</i> , 2014, 34, 1504-1512.	1.9	61

#	ARTICLE	IF	CITATIONS
37	Validation of Noninvasive Indices of Global Systolic Function in Patients With Normal and Abnormal Loading Conditions. <i>Circulation: Cardiovascular Imaging</i> , 2014, 7, 164-172.	1.3	55
38	Prognostic Factors in Compensated and Decompensated Cirrhosis. <i>Current Hepatology Reports</i> , 2014, 13, 171-179.	0.4	4
39	Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 487-495.	0.6	38
40	Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. <i>Hepatology</i> , 2013, 58, 2079-2088.	3.6	48
41	Comparison of MELD, HVPG, and their changes to predict clinically relevant endpoints in cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 204-211.	0.6	29
42	Esophageal Eosinophilic Infiltration Responds to Proton Pump Inhibition in Most Adults. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 110-117.	2.4	354
43	The management of portal hypertensive gastropathy and gastric antral vascular ectasia. <i>Digestive and Liver Disease</i> , 2011, 43, 345-351.	0.4	67
44	The heart in liver transplantation. <i>Journal of Hepatology</i> , 2011, 54, 810-822.	1.8	84
45	Prognostic Markers in Patients Who Have Recovered from an Acute Variceal Bleeding: Role of HVPG Measurement. <i>Disease Markers</i> , 2011, 31, 165-169.	0.6	3
46	Early transplanted liver performance and indocyanine green clearance. <i>Liver Transplantation</i> , 2010, 16, n/a-n/a.	1.3	0
47	A distinct nitric oxide and adenosine A1 receptor dependent hepatic artery vasodilatory response in the CCl4-cirrhotic liver. <i>Liver International</i> , 2010, 30, 988-994.	1.9	16
48	Management of Gastropathy and Gastric Vascular Ectasia in Portal Hypertension. <i>Clinics in Liver Disease</i> , 2010, 14, 281-295.	1.0	39
49	Risk factors for developing <i>de novo</i> autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 530-539.	1.3	52
50	Early noninvasive measurement of the indocyanine green plasma disappearance rate accurately predicts early graft dysfunction and mortality after deceased donor liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 1247-1253.	1.3	46
51	Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. <i>Journal of Hepatology</i> , 2009, 50, 923-928.	1.8	340
52	Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 689-695.	2.4	215
53	Serum levels of soluble vascular cell adhesion molecule are related to hyperdynamic circulation in patients with liver cirrhosis. <i>Liver International</i> , 2008, 28, 1129-1135.	1.9	16
54	Portal Hypertension-Related Complications After Acute Portal Vein Thrombosis: Impact of Early Anticoagulation. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1412-1417.	2.4	175

#	ARTICLE	IF	CITATIONS
55	Cardiac Dysfunction During Liver Transplantation: Incidence and Preoperative Predictors. <i>Transplantation</i> , 2008, 85, 1766-1772.	0.5	77
56	Value of the Hepatic Venous Pressure Gradient to Monitor Drug Therapy for Portal Hypertension: A Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2007, 102, 1116-1126.	0.2	137
57	The extent of the collateral circulation influences the postprandial increase in portal pressure in patients with cirrhosis. <i>Gut</i> , 2007, 56, 259-264.	6.1	24
58	Hepatic Venous Pressure Gradient and Outcomes in Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, S330-S335.	1.1	45
59	Use of Everolimus as a Rescue Immunosuppressive Therapy in Liver Transplant Patients With Neoplasms. <i>Transplantation</i> , 2007, 84, 786-791.	0.5	48
60	Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated Cirrhosis. <i>Gastroenterology</i> , 2007, 133, 481-488.	0.6	926
61	Treatment of gastropathy and gastric antral vascular ectasia in patients with portal hypertension. <i>Current Treatment Options in Gastroenterology</i> , 2007, 10, 483-494.	0.3	18
62	Prevalence of portal hypertensive duodenopathy in cirrhosis: clinical and haemodynamic features. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 649-653.	0.8	35
63	Does interferon improve portal hypertension?. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 7-12.	1.3	3
64	Antiviral Therapy Decreases Hepatic Venous Pressure Gradient in Patients with Chronic Hepatitis C and Advanced Fibrosis. <i>American Journal of Gastroenterology</i> , 2006, 101, 2269-2274.	0.2	150
65	Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. <i>Hepatology</i> , 2005, 42, 793-801.	3.6	213
66	Comparison of transjugular intrahepatic portosystemic shunt dysfunction in PTFE-covered stent-grafts versus bare stents. <i>European Journal of Radiology</i> , 2005, 55, 120-124.	1.2	95
67	Comparison of Transcatheter Arterial Embolization and Surgery for Treatment of Bleeding Peptic Ulcer after Endoscopic Treatment Failure. <i>Journal of Vascular and Interventional Radiology</i> , 2004, 15, 447-450.	0.2	183